radium has been researched along with Androgen-Independent Prostatic Cancer in 321 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 210 (65.42) | 24.3611 |
| 2020's | 111 (34.58) | 2.80 |
| Authors | Studies |
|---|---|
| Bauckneht, M; Cavallini, L; Cindolo, L; Costa, RP; De Vincentis, G; Donegani, MI; Fornarini, G; Frantellizzi, V; Gaudiano, A; Laghi, V; Lavelli, V; Licari, M; Lodi Rizzini, E; Maggi, M; Mammucci, P; Mascia, M; Monari, F; Murianni, V; Ponzano, M; Rebuzzi, SE; Rubini, G; Sambuceti, G; Sciarra, A; Signori, A; Spanu, A; Stazza, ML | 1 |
| Schiavom Duarte, P | 1 |
| Agarwal, N; Bruno, A; George, D; Guo, H; Higano, CS; Jiao, X; Miller, K; Saad, F; Sandström, P; Sartor, O; Shore, N; Sternberg, CN; Tombal, B; Verholen, F | 1 |
| Horio, T; Hosono, M; Kakehi, Y; Kinuya, S; Masumori, N; Okayama, Y; Sunaya, T; Takahashi, S; Uemura, H | 2 |
| Akakura, K; Ledesma, DA; Miyazaki, K; Seo, C; Stroupe, A; Uemura, H; Uzumcu, A | 1 |
| Abend, M; Barsegian, V; Eberlein, U; Hoffmann, MA; Lassmann, M; Majewski, M; Miederer, M; Nestler, T; Ostheim, P; Port, M; Rump, A; Schreckenberger, M | 1 |
| Maughan, BL | 1 |
| Aoki, M; Hashimoto, Y; Hatakeyama, S; Hatayama, Y; Ishibashi, Y; Ito, H; Kawaguchi, H; Kusaka, A; Noro, D; Ohyama, C; Okamoto, T; Okuyama, Y; Sasaki, D; Tanaka, T; Yamamoto, H; Yoneyama, T | 1 |
| Saganich, C; Zgaljardic, M | 1 |
| Antonarakis, ES; Bastos, DA; Camargo, AA; Gongora, ABL; Lopes, CDH; Marin, JF; Marshall, CH; Velho, PI | 1 |
| Bauckneht, M; Campi, C; Chiola, S; Cremante, M; D'Amico, F; Donegani, MI; Fornarini, G; Lai, R; Lanfranchi, F; Marini, C; Miceli, A; Morbelli, S; Piana, M; Raffa, S; Rebuzzi, SE; Sambuceti, G; Schenone, D; Zanardi, E | 1 |
| Iwamoto, H; Izumi, K; Kadomoto, S; Kadono, Y; Kano, H; Makino, T; Mizokami, A; Naito, R; Shimada, T; Yaegashi, H | 1 |
| Sartor, O | 4 |
| Huang, LH; Ou, YC; Tseng, NC; Weng, WC | 1 |
| Angusti, T; Bungaro, M; Buttigliero, C; DI Maio, M; DI Stefano, RF; Parente, A; Pisano, C; Samuelly, A; Scagliotti, GV; Tucci, M; Turco, F | 1 |
| Agarwal, N; Constantinovici, N; George, DJ; Guo, H; Higano, CS; Jiao, X; Miller, K; Reeves, J; Saad, F; Sandström, P; Sartor, O; Shore, N; Sternberg, CN; Tombal, B; Verholen, F | 1 |
| Angusti, T; Audisio, A; Audisio, M; Buttigliero, C; Di Maio, M; Di Stefano, RF; Parente, A; Parlagreco, E; Pisano, C; Samuelly, A; Scagliotti, GV; Tucci, M; Turco, F; Ungaro, A; Urban, S | 1 |
| Bambury, RM; Jamaluddin, MF; Kelly, P; Lyons, C; McCarthy, L; Peters, N; Power, DG | 1 |
| El Khouli, R; Kunos, CA; Lemieux, B; Liu, X; Myint, ZW; St Clair, WH; Yan, D | 1 |
| Bloom, JR; Castillejos, AG; Jones, B; Patel, N; Rosenstein, BS; Stock, RG | 1 |
| Bryce, AH; Choo, R; Ho, TH; Jaeger, E; Kendi, AT; Keole, SR; Kosiorek, HE; Ledet, E; Liu, AJ; Moore, CN; Quevedo, F; Sartor, O; Singh, P; Tzou, K; Ueberroth, BE; Wong, WW | 1 |
| Anderson, M; Cao, Y; Chang, M; Rojas, V; Trieu, J; Varada, N; Vogelzang, NJ | 1 |
| Custers, JAE; Gerritsen, WR; Janssen, MJR; Mehra, N; Oving, IM; Oyen, WJG; Prins, JB; Terheggen, F; van Basten, JP; van de Luijtgaarden, ACM; van den Berkmortel, F; van der Doelen, MJ; van Oort, IM; van Schelven, WD; Wyndaele, DNJ | 1 |
| Hasumi, H; Kawahara, T; Makiyama, K; Miyoshi, Y; Ninomiya, S; Sato, M; Takeshima, T; Uemura, H | 1 |
| Alonso-Gordoa, T; Bonfill, T; Borrega, P; Carles, J; Collado, R; Gallardo, E; Garcías de España, C; Garde, J; González-Del-Alba, A; Malfettone, A; Mellado, B; Méndez-Vidal, MJ; Morales-Barrera, R; Paredes, P; Piulats, JM; Reig, O; Sampayo-Cordero, M; Suárez, C; Vázquez, S | 1 |
| Doehn, C; Eichenauer, R; Grund, C; Hellmis, E; Hempel, E; Johannsen, M; Jores, C; Klier, J; König, F; Schönfelder, R; Schröder, J; Zillmann, R | 1 |
| Eriksson, MH; Garcia-Albeniz, X; Kjellman, A; Lissbrant, IF; Martinez, D; Sandstrom, P; Stattin, P; Ullén, A; Vassilev, Z; Weinrib, R; Westerberg, M | 1 |
| Kamoto, T; Kimura, T; Mukai, S; Nagano, M; Okabe, KO; Onizuka, C; Otuka, I; Shirakawa, T; Takamori, H; Terada, N; Ueno, T; Yamashita, Y | 1 |
| Bundschuh, RA; Dittmann, H; Eiber, M; Essler, M; Fendler, WP; Fougère, C; Hasa, E; Kurtinecz, M; Pabst, KM; Prasad, V; Rahbar, K; Rassek, P; Sartor, O; Schmall, A; Verholen, F | 1 |
| Blas, L; Eto, M; Hori, Y; Kiyoshima, K; Kuroiwa, K; Matsumoto, T; Morokuma, F; Nakamura, M; Seki, N; Shiota, M; Yokomizo, A | 2 |
| Choudhury, AD; Einstein, D; Kelly, WK; Knudsen, K; Leiby, B; Quinn, Z; Sartor, O; Sonpavde, G; Sweeney, C; Szmulewitz, R; Yang, ES | 1 |
| Daimon, T; Hosono, M; Igeta, M; Ishiwata, Y; Ito, K; Kawahara, T; Kitajima, K; Kono, Y; Kuyama, J; Miyake, H; Narita, M; Otani, T; Seko-Nitta, A; Suga, T; Sugawara, S; Tamaki, Y; Toriihara, A; Watanabe, S; Yamakado, K; Yamamoto, S | 1 |
| Danilenko, VV; Shypko, AF; Solodyannikova, OI; Sukach, GG | 1 |
| Gandaglia, G; Maggi, M; Marra, G; Martini, A; Rajwa, P | 1 |
| Attwood, K; George, S; Kothari, S; Lamonica, D; Levine, E; Shariftabrizi, A | 1 |
| Dai, JD; Shen, PF; Sun, GX; Wang, MH; Xu, NW; Zeng, H; Zeng, YH; Zhang, XM; Zhao, JG | 1 |
| K Das, M; Mandal, S; Nayak, P; Ram, P | 1 |
| Chen, CH; Chen, IA; Chen, YH; Chen, YT; Cheng, YT; Chiang, PC; Chiang, PH; Kang, CH; Liu, YY; Luo, HL; Su, YL; Wang, HJ | 1 |
| Alhoniemi, E; Haendler, B; Käkönen, SM; Knuuttila, M; Mumberg, D; Schatz, CA; Schlicker, A; Scholz, A; Sjöholm, B; Suominen, MI; Vääräniemi, J | 1 |
| Briones, J; Emmenegger, U; Hardisty, MR; Khan, M; Lyons, F; Naimi, MF; Parshad, S; Phillips, CM; Sidhu, AK; Smoragiewicz, M; Whyne, CM | 1 |
| Abramowitz, E; O'Sullivan, JM; Sierra-Scacalossi, L | 1 |
| Chang, LW; Chen, CC; Chen, CS; Cheng, CL; Chiu, KY; Hung, SC; Li, JR; Lin, CY; Lu, K; Ou, YC; Wang, SC; Wang, SS; Yang, CK; Yang, HC | 1 |
| Chang, YH; Chung, HJ; Huang, EY; Huang, WJ; Lin, TP; Wei, TT; Yu, PH | 1 |
| Yuasa, T | 1 |
| Alonzi, R; Blackledge, MD; Chatfield, P; Chua, S; Cook, GJR; Curcean, A; Du, Y; Finch, J; Hafeez, S; Hall, E; Koh, DM; Murray, I; Padhani, AR; Parker, C; Perry, S; Staffurth, J; Stidwill, H; Tovey, H; Tree, A; Tunariu, N | 1 |
| Carles, J; Cathomas, R; Gomez-Iturriaga, A; Heinrich, D; Kramer, G; O'Sullivan, JM; Ost, P; Tombal, B; van Oort, I | 1 |
| Frank, SJ; Heinrich, D; Keizman, D; Li, R; Mariados, N; Méndez Vidal, MJ; Nordquist, LT; Peer, A; Procopio, G; Pulkkanen, K; Rosenbaum, E; Sartor, O; Severi, S; Thellenberg Karlsson, C; Trandafir, L; Trigo, J; Wagner, V | 1 |
| Dizdarevic, S; McCready, R; Vinjamuri, S | 1 |
| Fujii, Y; Hinotsu, S; Izumi, K; Kimura, G; Mizokami, A | 1 |
| Figg, WD; Knechel, MA; Schmidt, KT | 1 |
| Barata, PC; Christensen, BR; Layton, JL; Ledet, EM; Lewis, BE; Sartor, O | 1 |
| Fricke, E; Goebell, PJ; Johannsen, M; Klier, J; König, F; Mehl, S; Mommsen, C; Pfister, D; Sahlmann, CO; Strauß, A; Werner, A | 1 |
| Borsellino, N; Costa, R; Gebbia, V; Licari, M; Murabito, A; Princiotta, A; Sanfilippo, C; Scalici Gesolfo, C; Serretta, V; Tripoli, V; Valerio, MR; Verderame, F | 1 |
| Corey, E; Guise, TA; Gulley, JL; Kevin Kelly, W; Morris, MJ; Quinn, DI; Scholz, A; Sgouros, G | 1 |
| Hosono, M; Kakehi, Y; Kikukawa, H; Kimura, G; Kinuya, S; Krissel, H; Matsubara, N; Mizokami, A; Nagamori, S; Nakamura, M; Siegel, J; Uemura, H | 1 |
| Aloise, I; Colosi, M; Farcomeni, A; Frantellizzi, V; Ippoliti, MD; Pani, A; Pani, R; Polito, C; Vincentis, G | 1 |
| Badrising, SK; Beeker, A; Bergman, AM; Celik, F; Coenen, JLLM; Haanen, JB; Hamberg, P; Lam, MGEH; Loosveld, OJL; Louhanepessy, RD; Oostdijk, A; van der Noort, V; Vegt, E; Wagenaar, N; Zuetenhorst, H; Zwart, W | 1 |
| Agarwal, N; Batten, J; Boucher, K; Gupta, S; Haaland, B; Hahn, AW; Hawks, J; Hoffman, JM; Maughan, BL; Morton, K; Nachaegari, G; Nussenzveig, R; Santos, VS; Thorley, J; Wang, X | 1 |
| Davis, ID; Epstein, RJ; Graff, JN; Gurney, H; Hussain, M; Leung, E; Peer, A; Rosenbaum, E; Saad, F; Sternberg, CN; Trandafir, L; Vaishampayan, UN; Wagner, VJ; Wu, B | 1 |
| Casadei, C; Cursano, MC; De Giorgi, U; Iuliani, M; Paganelli, G; Santini, D; Stellato, M; Tonini, G | 1 |
| Albano, D; Bertagna, F; Cerudelli, E; Cossalter, E; Durmo, R; Gazzilli, M; Giubbini, R; Panarotto, MB | 1 |
| Bagni, O; Basile, P; Filippi, L; Schillaci, O | 1 |
| Aliberti, G; Apollonio, G; Claps, M; Maccauro, M; Pagani, F; Peverelli, G; Procopio, G; Raimondi, A; Randon, G; Sepe, P; Seregni, E; Verzoni, E | 1 |
| Brito, AE; Etchebehere, E | 1 |
| Cindolo, L; Costa, R; De Vincentis, G; Farcomeni, A; Frantellizzi, V; Licari, M; Mascia, M; Nuvoli, S; Pontico, M; Spanu, A | 1 |
| Abou, DS; Finley, PA; Jha, AK; Riddle, RC; Rittenbach, A; Simons, BW; Thorek, DLJ; Tomlinson, RE; Tsui, B; Ulmert, D | 1 |
| Chiti, A; Gelardi, F; Mazziotti, G; Pepe, G; Rodari, M; Tosi, G; Zucali, PA | 1 |
| Agostini, S; Alongi, P; Baldari, S; Biasco, E; Borsatti, E; Bortolus, R; Caffo, O; Cortesi, E; De Vincentis, G; Facchini, G; Fanti, S; Filice, A; Frantellizzi, V; Galli, L; Masini, C; Monari, F; Pignata, S; Rossetti, S; Spada, M; Tucci, M; Zichi, C | 1 |
| Dionisi, V; Fanti, S; Ghedini, P; Monari, F; Morganti, AG; Rizzini, EL | 1 |
| Andreola, M; Cindolo, L; Cosma, L; Costa, R; De Vincentis, G; Dionisi, V; Farcomeni, A; Frantellizzi, V; Lavelli, V; Lodi Rizzini, E; Mascia, M; Monari, F; Murabito, A; Nappi, AG; Nuvoli, S; Rubini, G; Spanu, A | 1 |
| Dorff, TB; Kortylewski, M; Posadas, E; Quinn, D; Stein, C; Synold, T | 1 |
| Ahmadzadehfar, H; Baum, RP; Bögemann, M; Fimmers, R; Garcia-Perez, FO; Gerke, C; Ilhan, H; Kabasakal, L; Kairemo, K; Kessel, K; Kratochwil, C; Kulkarni, HR; Maffey-Steffan, J; Maharaj, M; Paez, D; Rahbar, K; Rathke, H; Sathekge, M; Seifert, R; Virgolini, I; Zhang, J | 1 |
| George, DJ; Higano, CS; Jiao, X; Kalinovsky, J; Miller, K; Saad, F; Sartor, O; Shore, N; Sternberg, CN; Tangirala, K; Tombal, B | 1 |
| Atkinson, S; Azzabi, A; Burns, A; Cumming, S; Frew, J; Jiang, XY; Leaning, D; McMenemin, R; Pearson, R; Pedley, ID | 1 |
| Abou Chakra, M; Dellis, A; Moussa, M; Papatsoris, A; Sryropoulou, D | 1 |
| Aben, KK; Bergman, AM; Celik, F; Coenen, JL; den Bosch, JV; der Meer, SV; Gerritsen, WR; Hendriks, MP; Kuppen, MC; Lavalaye, J; Polee, MB; Somford, DM; Uyl-de Groot, CA; van den Bergh, AC; van den Eertwegh, AJ; van der Doelen, MJ; van Oort, IM; Westgeest, HM | 1 |
| Harrelson, SS; Mariados, NF; Schellhammer, PF; Shore, ND; Tutrone, RF | 1 |
| Antonarakis, ES; Bormann, M; Gerritsen, WR; Isaacsson Velho, P; Kroeze, LI; Mehra, N; Pamidimarri Naga, S; Slootbeek, PHJ; van der Doelen, MJ; van Helvert, S; van Oort, IM | 1 |
| Cindolo, L; Costa, R; De Angelis, C; De Vincentis, G; Di Rocco, A; Dionisi, V; Ferrari, C; Frantellizzi, V; Lavelli, V; Licari, M; Lodi Rizzini, E; Mascia, M; Monari, F; Nuvoli, S; Rubini, G; Spanu, A | 1 |
| Kuker, R; Serafini, A; Wang, J | 1 |
| Hashimoto, K; Naito, M; Ukai, R | 1 |
| Dandapani, SV; Twardowski, P; Wong, J | 1 |
| Appukkuttan, S; Bhak, RH; Cheng, M; Duh, MS; Korves, C; McKay, RR; Silver, R; Simmons, SJ; Taplin, ME | 1 |
| Bagni, O; Chiaravalloti, A; Filippi, L; Schillaci, O | 1 |
| Kakimoto, KI; Kanaki, T; Nagahara, A; Nakai, Y; Nakayama, M; Nishimura, K; Okuda, Y; Tanaka, R; Yamamoto, Y | 1 |
| Ahmadzadehfar, H; Conrad, R; Essler, M; Herrmann, K; Hirmas, N; Marinova, M; Sraieb, M | 1 |
| Fukuta, F; Hashimoto, K; Hinotsu, S; Hori, M; Hotta, H; Kato, R; Kitamura, H; Kobayashi, K; Kunishima, Y; Maehana, T; Masumori, N; Miyamoto, S; Miyoshi, Y; Nishiyama, N; Okada, M; Sakata, KI; Shindo, T; Takahashi, A; Tanaka, T; Tsuboi, Y; Uemura, H; Yanase, M | 1 |
| De Vincentis, G; Frantellizzi, V; Lazri, J; Pani, A; Pontico, M | 1 |
| Chen, CH; Ding, Q; Guo, H; Guo, J; Jiang, Y; Krissel, H; Lee, JL; Li, F; Li, H; Li, R; Liu, X; Ma, J; Ng, QS; Park, SH; Shi, H; Sun, Y; Tian, Y; Wagner, VJ; Wang, S; Yao, X; Yuan, J; Zhang, X; Zheng, R; Zhou, D; Zhou, F; Zhou, T; Zou, Q | 1 |
| Cindolo, L; Costa, R; De Vincentis, G; Dionisi, V; Farcomeni, A; Frantellizzi, V; Lavelli, V; Licari, M; Lodi Rizzini, E; Mascia, M; Monari, F; Nappi, AG; Nuvoli, S; Ricci, M; Rubini, G; Spanu, A | 1 |
| Ho, A; Jarvis, P; Sundram, F | 1 |
| De Vincentis, G; Frantellizzi, V | 1 |
| Mehra, N; Slootbeek, PHJ; van der Doelen, MJ | 1 |
| Afful, M; Antonarakis, ES; Armstrong, AJ; Barata, PC; Cotogno, P; DeWeese, TL; Drake, CG; Fu, W; Hurrelbrink, J; King, S; Manogue, C; Marshall, CH; Moldawer, NP; Park, JC; Posadas, EM; Sartor, O; Song, DY; Tran, PT; Wang, H | 1 |
| Alongi, F; Alongi, P; Baldari, S; Biasco, E; Borsatti, E; Bortolus, R; Caffo, O; Cortesi, E; Costa, RP; Facchini, G; Fanti, S; Filice, A; Frantellizzi, V; Monari, F; Murabito, A; Palermo, A; Pignata, S; Pinto, C; Salgarello, M; Sbrana, A; Spada, M; Tucci, M; Vincentis, G; Zichi, C | 1 |
| Bagni, O; Basile, P; Chiaravalloti, A; Filippi, L; Schillaci, O | 1 |
| Abouassaly, R; Bryk, DJ; Ericson, K; Fascelli, M; Haywood, SC; Khanna, A; Murthy, PB; O'Connor, LP; Yerram, NK | 1 |
| Ahmed, ME; Badawy, M; Joshi, VB; Karnes, RJ; Kendi, AT; Kwon, ED; Lowe, V; Pagliaro, LC; Thorpe, MP | 1 |
| Hayashi, N; Kawahara, T; Miyoshi, Y; Nozawa, M; Tsutsumi, S; Uemura, H; Uemura, KI; Yasui, M; Yoshimura, K | 1 |
| Gerritsen, WR; Ma, Y; Mehra, N; Nilsson, S; Stockhaus, A; Ullén, A; van der Doelen, MJ; van Oort, IM; Yachnin, J | 1 |
| Amling, CL; Aronson, WJ; Cooperberg, MR; De Hoedt, AM; Freedland, SJ; Howard, LE; Kane, CJ; Klaassen, Z; Polascik, TJ; Terris, MK; Vidal, AC; Zhao, H | 1 |
| Albany, C; Dawson, NA; Higano, CS; Mehlhaff, BA; Nordquist, LT; Patel, KR; Petrylak, DP; Quinn, DI; Sartor, O; Siegel, J; Trandafir, L; Vaishampayan, UN; Wagner, VJ | 1 |
| Aben, KKH; Bergman, AM; Coenen, JLLM; de Wit, R; Gerritsen, WR; Kuppen, MCP; Mehra, N; Somford, DM; Uyl-de Groot, CA; van den Bergh, ACM; van den Eertwegh, AJM; van Moorselaar, RJA; van Oort, IM; Westgeest, HM | 1 |
| Abrantes, AM; Botelho, MF; Caramelo, FJ; Costa, G; Figueiredo, A; Gonçalves, AC; Marques, IA; Matafome, P; Neves, AR; Pereira, CC; Pires, AS; Rodrigues, T; Seiça, R; Tavares-da-Silva, E; Teixeira, JP | 1 |
| Alongi, F; Alongi, P; Baldari, S; Borsatti, E; Bortolus, R; Caffo, O; Cortesi, E; Costa, RP; De Giorgi, U; De Vincentis, G; Donner, D; Facchini, G; Fanti, S; Frantellizzi, V; Galli, L; Lo Re, G; Masini, C; Monari, F; Morabito, A; Pignata, S; Pinto, C; Salgarello, M; Sbrana, A; Spada, M; Tucci, M; Zichi, C | 1 |
| Alonzi, R; Blackledge, M; Chatfield, P; Curcean, S; Finch, J; Hall, E; Hijab, A; Mu Koh, D; Padhani, A; Parker, C; Perry, S; Staffurth, J; Stidwill, H; Tovey, H; Tree, A; Tunariu, N | 1 |
| Appukkuttan, S; Sartor, O; Tsao, CK; Weiss, J | 1 |
| Ahmadzadehfar, H; Baum, RP; Bögemann, M; Garcia-Perez, FO; Ilhan, H; Kabasakal, L; Kairemo, K; Kessel, K; Kratochwil, C; Maharaj, M; Matern, R; Paez, D; Rahbar, K; Rathke, H; Sathekge, M; Seifert, R; Svirydenka, H; Virgolini, I; Yordanova, A | 1 |
| Basch, E; Heller, G; McHugh, D; Milowsky, M; Morris, MJ; Moryl, N; Osborne, J; Pandit-Taskar, N; Rathkopf, D; Tagawa, S | 1 |
| Alva, A; Appleman, LJ; Armstrong, AJ; Datye, A; Fong, L; Higano, CS; Kadel, EE; Morris, MJ; Pagliaro, L; Petrylak, DP; Porcu, R; Sartor, O; Tan, W; Tayama, D; Vaishampayan, U; Yuen, KC | 1 |
| Basch, EM; Brower, B; Crona, DJ; Dunn, MW; Godley, PA; Khandani, AH; Kim, SI; Milowsky, MI; Morgan, KP; Rose, TL; Szeto, AH; Whang, YE | 1 |
| Alibhai, SMH; Breunis, H; Emmenegger, U; Feng, G; Fleshner, N; Gregg, R; Hansen, A; Joshua, A; Timilshina, N; Tomlinson, G; Warde, P | 1 |
| Al-Ezzi, EM; Alqaisi, HA; Catton, CN; Fallah-Rad, N; Fleshner, NE; Hamilton, RJ; Hansen, AR; Iafolla, MAJ; Jiang, DM; Sacher, AG; Sridhar, SS; Wang, L; Warde, PR; Watson, GA; Zlotta, AR | 1 |
| Badrising, SK; Beeker, A; Bergman, AM; Celik, F; Coenen, JLLM; de Feijter, JM; Dezentjé, VO; Haanen, JB; Hamberg, P; Kieffer, J; Lam, M; Loosveld, OJL; Louhanepessy, RD; Oostdijk, A; Ras-van Spijk, S; van de Poll-Franse, LV; van der Noort, V; Vegt, E; Wagenaar, N; Zuetenhorst, H; Zwart, W | 1 |
| Armstrong, A; Balk, M; Brown, B; Bui, C; Chambers, J; Deangelis, J; Fitch, K; Flanders, S; Sawhney, TG | 1 |
| Choudhury, A; Ellis, T; Logue, J; Mbanu, P; Parikh, O; Song, YP; Walshaw, R | 1 |
| Amthauer, H; Genseke, P; Großer, OS; Kupitz, D; Ricke, J; Ruf, J; Wallbaum, T; Wissel, H | 1 |
| Baldari, S; Boni, G; Bortolus, R; Caffo, O; Conti, G; De Vincentis, G; Monari, F; Procopio, G; Santini, D; Seregni, E; Valdagni, R | 1 |
| Adamo, V; Baldari, S; Caffo, O; Franchina, T; Picciotto, M; Provazza, G; Ricciardi, GRR; Russo, A; Sava, S | 1 |
| Bruland, Ø; Coleman, RE; Heinrich, D; Helle, SI; Kattan, MW; Kobina, S; Nilsson, S; O'Sullivan, JM; Parker, C; Sartor, O; Shan, M; Vogelzang, NJ; Wilhelm, S; Xu, L | 1 |
| Doi, T; Hosono, M; Kinuya, S; Matsubara, N; Uemura, H; Yajima, Y | 1 |
| García Cañamaque, L; García De la Peña, P; Rioja Parada, C | 1 |
| Izumi, K; Kadono, Y; Kitagawa, Y; Konaka, H; Mizokami, A | 1 |
| Hinz, S | 1 |
| Carrio, I; De Vincentis, G; Du, Y; Fanti, S; Ilhan, H; Lewington, V; Mommsen, C; Nitzsche, E; Oyen, W; Sundram, F; Vogel, W | 1 |
| Saad, F; Traboulsi, SL | 1 |
| Vogelzang, NJ | 1 |
| Cozar-Olmos, JM; Figueiredo-de Castro, A; Juárez-Soto, A; Miñana-López, B; Rodríguez-Antolín, A; Silva-Marins, C; Sousa-Campo, R; Unda-Urzaiz, M | 1 |
| Fukasawa, S; Hosono, M; Kawasaki, Y; Kikukawa, H; Kimura, G; Kinuya, S; Kosaka, T; Masumori, N; Matsubara, N; Mizokami, A; Nagamori, S; Nasu, Y; Sugiyama, T; Tsutsui, H; Uemura, H; Wakumoto, Y; Yamaguchi, I; Yokomizo, A; Yonese, J | 1 |
| Ko, EC; Ryan, CJ; Wei, XX | 1 |
| Alvarez Cabellos, R; García Vicente, AM; Mohedano Mohedano, N; Sanchez Gil, B; Soriano Castrejón, Á | 1 |
| Fosbøl, MØ; Kjaer, A; Mortensen, J; Petersen, PM | 1 |
| Coel, MN; Kwee, SA; Lim, J | 1 |
| Beuzeboc, P; Cachin, F; Deshayes, E; Hennequin, C; Houédé, N; Huglo, D; Kassab-Chahmi, D; Rebillard, X; Roumiguie, M; Rozet, F; Thibault, C | 1 |
| George, DJ | 1 |
| Frank, SJ; Heinrich, D; Keizman, D; Li, R; Mariados, N; Méndez Vidal, MJ; Nordquist, LT; Peer, A; Procopio, G; Pulkkanen, K; Rosenbaum, E; Sartor, O; Severi, S; Thellenberg Karlsson, C; Trigo Perez, JM; Wagner, V | 1 |
| Daugaard, G; Fosbøl, MØ; Holm, S; Kjaer, A; Mortensen, J; Petersen, PM | 1 |
| Grimm, MO; von Rundstedt, FC; Winter, BM | 1 |
| Cha, TL; Chang, WY; Huang, CY; Huang, SP; Lin, CC; Ou, YC; Pang, ST; Shen, DH; Vogelzang, NJ; Wu, TT; Wu, WJ | 1 |
| Carles, J; Climent, MÁ; Olmos, D; Pinto, Á; Rodriguez-Vida, A; Torregrosa, MD | 1 |
| Kang, I; Kang, Y; Kim, JW; Petrylak, DP; Shin, MS | 1 |
| Gerritsen, WR; Janssen, MJR; Jonker, MA; Kuppen, MCP; Mehra, N; van der Doelen, MJ; van Oort, IM | 1 |
| Ichimura, A; Jinzaki, M; Nakahara, T; Nakajima, K; Owaki, Y | 1 |
| Poon, DMC; Wong, KCW | 1 |
| Chittenden, SJ; Flux, GD; Hindorf, C; Parker, CC; Pratt, BE | 1 |
| Harrelson, SS; Mariados, NF; Mehlhaff, BA; Nordquist, LT; Shore, ND; Steere, KJ; Tutrone, RF | 1 |
| Arranz, JA; Carles, J; Castellano, D; Del Alba, AG; Donas, JG; Esteban, E; Germà, JR; Hernando, S; Laínez, N; León, L; López-Brea, M; López-Criado, P; Maroto, P; Mellado, B; Méndez, MJ; Moretones, C; Pérez-Gracia, JL; Pérez-Valderrama, B; Pinto, Á; Reynés, G; Sáez, MI | 1 |
| Andreeff, M; Becherer, A; Bockisch, A; Bodei, L; Delgado-Bolton, RC; Fricke, E; Gabriel, M; Geworski, L; Handkiewicz-Junak, D; Heinzel, A; Krause, BJ; Krause, T; Mitterhauser, M; Poeppel, TD; Sonnenschein, W | 1 |
| Cicero, G; Costa, RP; De Luca, R; Murabito, A; Tripoli, V | 1 |
| Azuma, H; Ibuki, N; Inamoto, T; Kantoff, PW; Komura, K; Sweeney, CJ | 1 |
| De Vincentis, G; Farcomeni, A; Follacchio, GA; Frantellizzi, V; Pacilio, M; Pani, R; Pellegrini, R | 1 |
| Mostaghel, EA; Pritchard, CC; Ramos, JD; Yu, EY | 1 |
| Heidenreich, A; Nilsson, S; Parker, C; Shore, N | 1 |
| Coleman, RE; Den, R; Logothetis, C; Morris, MJ | 1 |
| Amorim, BJ; Bernardo, WM; Brito, AE; Etchebehere, E; Martello, M | 1 |
| Gomella, L; Jacene, H; Rohren, EM; Yu, EY | 1 |
| Fukada, J; Ichimura, A; Jinzaki, M; Kosaka, T; Nakahara, T; Owaki, Y | 1 |
| Gillessen, S; Isensee, G; Müller, J; Omlin, A; Péporté, A; Schmid, S | 1 |
| Mulders, PFA; Niepel, D; Saad, F; Sternberg, CN; Tombal, BF | 1 |
| Bauriaud-Mallet, M; Ben Bouallègue, F; Brillouet, S; Caselles, O; Courbon, F; Dierickx, L; Gabiache, E; Kanoun, S; Pascal, P; Sinigaglia, M; Tal, I; Vallot, D; Vija Racaru, L; Zerdoud, S | 1 |
| Abrantes, AM; Botelho, MF; Figueiredo, A; Marques, IA; Neves, AR; Pires, AS; Tavares-da-Silva, E | 1 |
| Baldari, S; Conti, G; Cortesi, E; De Vincentis, G; Frantellizzi, V; Monari, F; Napolitano, S; Reale, L; Salgarello, M; Salvi, E | 1 |
| de Iturriaga, AG; Mínguez, P; Mínguez, R; Rodeño, E; Roeske, JC | 1 |
| Bottomley, D; Din, O; Dixit, S; Ferguson, C; Handforth, C; Henry, AM; Joseph, L; Kenning, L; Mokhtar, D; Murray, L; Parikh, S; White, L; Wright, G | 1 |
| Etchebehere, E; Kairemo, K; Macapinlac, HA; Milton, DR; Rohren, EM | 1 |
| Franklin, GE; Rathbun, JT | 1 |
| Begley, P; Dizdarevic, S; Jessop, M; Main, S; Robinson, A | 1 |
| Álvarez-Ossorio, JL; Carballido-Rodríguez, J; Cozar-Olmo, JM; Gómez-Veiga, F; Juárez-Soto, A; Rodríguez-Antolín, A | 1 |
| Arranz, JÁ; Carles, J; Castellano, D; González Del Alba, A; Jimenez, J; López, C; Manneh, R; Mellado, B; Méndez-Vidal, MJ; Morales-Barrera, R; Perez-Gracia, JL; Porras, I; Saez, MI; Sepúlveda, JM; Suárez, C | 1 |
| Ferretti, A; Gross, MD; Rubello, D; Viglianti, BL; Wale, DJ; Wong, KK | 1 |
| Antonarakis, ES; Carducci, MA; Denmeade, SR; DeWeese, TL; Eisenberger, MA; Hassan, S; Isaacsson Velho, P; Markowski, MC; Qazi, F; Song, DY; Thorek, DL; Tran, PT | 1 |
| Camargo Ibargarai, I; Lacasa-Viscasillas, I; Loizaga-Iriarte, A; Senarriaga-Ruiz de la Illa, N; Unda-Urzaiz, M | 1 |
| Kratochwil, C; Levy, M; Lewington, V; Lindén, O; Noordzij, W; Park, J; Parker, C; Saad, F; Shore, N | 1 |
| Alongi, F; Baier, S; Basso, U; Borsatti, E; Caffo, O; De Vivo, R; Evangelista, L; Fratino, L; Galuppo, S; Iacovelli, R; Maines, F; Maruzzo, M; Nicodemo, M; Palleschi, D; Sava, T; Sorarù, M; Zagonel, V; Zivi, A; Zustovich, F | 1 |
| Hosono, M; Ikebuchi, H; Kinuya, S; Nakamura, Y; Yanagida, S | 1 |
| Iizuka, J | 1 |
| Bryce, AH; Dorff, TB; Groshen, S; Ji, L; Quinn, DI; Wong, W; Yap, KK | 1 |
| Bloemendal, HJ; Bouman-Wammes, EW; de Klerk, JMH; Lange, R; Ter Heine, R; Van den Eertwegh, AJM; Van Dodewaard-de Jong, JM; Verheul, HMW | 1 |
| Bulzonetti, N; De Vincentis, G; Frantellizzi, V; Ricci, M | 1 |
| Gerritsen, WR; Hermsen, R; Janssen, MJR; Mehra, N; van der Doelen, MJ; van Oort, IM | 1 |
| Carles, J; Gillessen, S; Heidenreich, A; Heinrich, D; Keizman, D; Miller, K; Nilsson, S; O'Sullivan, JM; Reeves, J; Saad, F; Seger, M; Wirth, M | 2 |
| Bayh, I; Bourre, JC; Dizdarevic, S; Du, Y; Essler, M; Ezziddin, S; Kalinovský, J; la Fougère, C; Paganelli, G; Petersen, PM; Valdagni, R; Versari, A | 1 |
| Berruti, A; Dalla Volta, A; Formenti, AM | 1 |
| Ahmadzadehfar, H; Bundschuh, RA; Essler, M; Glanert, T; Hirzebruch, S; Kürpig, S; Rödel, R; Scholl, C; Thomas, L; Wei, X | 1 |
| Buttigliero, C; Caffo, O; Cavaliere, C; D'aniello, C; Di Maio, M; Facchini, G; Kinspergher, S; Maines, F; Rizzo, M; Rossetti, S; Scagliotti, GV; Tucci, M; Veccia, A | 1 |
| Boegemann, M; Heidenreich, A; Higano, C; Kakehi, Y; Karyakin, O; Kimura, G; Krissel, H; Matsubara, N; Matveev, V; Miller, K; Nahas, WC; Ng, QS; Nolè, F; Parker, C; Piulats, JM; Rosenbaum, E; Saad, F; Shen, J; Smith, M; Teufel, M; Tombal, B; Wagner, V; Zhang, A; Zucca, LE | 1 |
| Spratt, DE | 1 |
| Den, RB; George, D; McNamara, M; Pieczonka, C | 1 |
| Boni, G; Monari, F | 1 |
| Akagawa, T; Fukasawa, S; Hosono, M; Kawasaki, Y; Kikukawa, H; Kimura, G; Kinuya, S; Kosaka, T; Masumori, N; Matsubara, N; Mizokami, A; Nagamori, S; Nasu, Y; Sugiyama, T; Uemura, H; Wakumoto, Y; Yamaguchi, I; Yokomizo, A; Yonese, J | 1 |
| Leibowitz-Amit, R | 1 |
| Bellarosa, C; Cardano, R; Dionisi, V; Fanti, S; Ghedini, P; Monari, F; Morganti, AG; Rizzini, EL | 1 |
| Cursano, MC; De Giorgi, U; Iuliani, M; Paganelli, G; Santini, D | 1 |
| Hindié, E; Morgat, C | 1 |
| Anand, A; Anand, M; Armstrong, AJ; Chin, BB; George, DJ; McNamara, MA; Oldan, J; Oyekunle, T; Ritz, M; Shantzer, L | 1 |
| Antonarakis, ES; Carrasquillo, JA; Deandreis, D; Fizazi, K; Higano, CS; Jacene, HA; Loriot, Y; Lu, C; Morris, MJ; Pandit-Taskar, N; Petrenciuc, O; Ryan, CJ; Shevrin, DH; Sweeney, CJ; Vesselle, H | 1 |
| Iijima, M; Iwamoto, H; Izumi, K; Kadomoto, S; Kadono, Y; Kawaguchi, S; Makino, T; Matsuo, S; Mizokami, A; Nakashima, K; Nohara, T; Shigehara, K; Yaegashi, H | 1 |
| Colasurdo, AP; Gallicchio, R; Guglielmi, G; Landriscina, M; Mainenti, PP; Mastrangelo, PA; Nardelli, A; Storto, G | 1 |
| Anand, M; Armstrong, AJ; Davies, C; Foo, WC; George, DJ; Gerber, D; Giannakakou, P; Gregory, SG; Gupta, S; Halabi, S; Healy, P; Kemeny, G; Leith, B; Ribar, T; Rothwell, C; Somarelli, JA; Spritzer, C; Ware, K; Wood, K; Zalutsky, MR; Zhang, J | 1 |
| Cortesi, E; De Vincentis, G; Farcomeni, A; Follacchio, GA; Frantellizzi, V; Pani, A; Samaritani, R; Santini, D; Schinzari, G | 1 |
| Miranda, J; Pinto, Á; Viñal, D | 1 |
| Morgan, SC | 1 |
| Tombal, B; Van den Wyngaert, T | 1 |
| Chittenden, SJ; Flux, GD; Gear, J; Murray, I; Parker, CC; Taprogge, J | 1 |
| van der Poel, H | 1 |
| Agarwal, N; Bellmunt, J; DiLorenzo, G; Sonpavde, G; Vogelzang, NJ; Zhang, TY | 1 |
| Aksnes, AK; Carrasquillo, JA; Humm, JL; Lacuna, K; Larson, SM; Morris, MJ; O'Donoghue, JA; Pandit-Taskar, N; Rathkopf, DE; Scher, HI; Slovin, SF; Williamson, MJ | 1 |
| Joshua, AM; Leibowitz-Amit, R | 1 |
| Higano, C | 1 |
| Al-Hakim, A; Alebachew, E; Chen, W; Haber, MT; Ibrahim, A; Justice, R; Kluetz, PG; Leutzinger, EE; Liu, Q; Maher, VE; Palmby, T; Pazdur, R; Pierce, W; Song, P; Sridhara, R; Tang, S; Zhang, H | 1 |
| Bahl, A | 1 |
| Aksnes, AK; Awadallah, R; Biggin, C; Carrasquillo, J; Dauer, LT; Ghani, R; Humm, J; Morris, M; O'Donoghue, J; Pandit-Taskar, N; Reinton, V; St Germain, J; Williamson, MJ | 1 |
| Heinzer, H; Klutmann, S; König, F | 1 |
| McCormack, PL; Shirley, M | 1 |
| Gurney, H; Parente, P; Parnis, F | 1 |
| Den, RB; Doyle, LA; Knudsen, KE | 1 |
| Bruland, ØS; Chodacki, A; Coleman, R; Fosså, SD; Heinrich, D; Helle, SI; Hoskin, P; James, ND; Johannessen, DC; Logue, J; Nilsson, S; O'Bryan-Tear, CG; O'Sullivan, JM; Parker, C; Sartor, O; Shan, M; Solberg, A; Syndikus, I; Vogelzang, NJ; Widmark, A; Wiechno, P | 1 |
| Logothetis, CJ | 1 |
| Nilsson, S | 2 |
| Blank, PR; Puri, D; Szucs, TD | 1 |
| Boni, G; Borsò, E; Cianci, C; Falcone, A; Farnesi, A; Galli, L; Mariani, G; Mazzarri, S; Ricci, S | 1 |
| Gartrell, BA; Saad, F | 1 |
| Everly, JJ; Ryan, CJ; Sartor, O; Saylor, PJ | 1 |
| Alcaraz, A; Caffo, O; da Silva, FC; Hammerer, P; Merseburger, AS; Roumeguère, T; Rozet, F | 1 |
| Højgaard, L; Mortensen, J | 1 |
| Beer, TM; Graff, JN | 2 |
| Den, RB; Kelly, WK | 1 |
| Aksnes, AK; Bottomley, D; Fang, F; Helle, SI; Hoskin, P; Johannessen, DC; Logue, J; Nilsson, S; O'Sullivan, JM; Parker, C; Sartor, O; Vogelzang, NJ; Wahba, M | 1 |
| Baba, S; Honda, H; Nakamura, K; Ohga, S; Sasaki, T | 1 |
| Afonso Afonso, FJ; Anido Herranz, U; Antón Aparicio, LM; Fernández Calvo, O; Lázaro Quintela, M; León Mateos, L; Rodríguez Martínez de Llano, S; Vázquez Estévez, S | 1 |
| Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Horton, ER; McGann, S | 1 |
| Böker, A; Kuczyk, MA; Merseburger, AS; von Klot, CA | 1 |
| Bilusic, M; Chen, D; Ito, T | 1 |
| Shore, ND | 2 |
| Osborne, JR; Spratt, DE | 1 |
| Dan, TD; Den, RB; Dicker, AP; Eldredge-Hindy, HB; Gomella, LG; Hoffman-Censits, J; Hurwitz, MD; Kelly, WK; Lallas, CD; Lin, J; Trabulsi, EJ | 1 |
| Slovin, SF; Yeku, O | 1 |
| Challa, S; Conti, PS; Jadvar, H; Quinn, DI | 1 |
| Taneja, SS | 1 |
| Hall, NC; Monk, JP; Murrey, DA; Wright, CL | 1 |
| Bergeron, DE; Cessna, JT; Fitzgerald, R; King, L; Pibida, L; Zimmerman, B | 1 |
| Bruland, OS; Humm, JL; Macklis, R; Parker, C; Sartor, O | 1 |
| Arauz, G; Curley, T; Delacruz, A; Jensen, T; Lindo, A | 1 |
| George, DJ; McNamara, MA | 1 |
| Dorff, TB; Gross, ME | 1 |
| Chopra, S; Rashid, P | 1 |
| Attard, G; de Bono, JS; Lorente, D; Mateo, J; Perez-Lopez, R | 1 |
| Araujo, JC; Etchebehere, EC; Fox, PS; Macapinlac, HA; Rohren, EM; Swanston, NM | 1 |
| Body, JJ; Casimiro, S; Costa, L | 1 |
| Chittenden, SJ; Flux, GD; Hindorf, C; Johnson, B; Lewington, VJ; Parker, CC; Pratt, BE | 1 |
| Crawford, ED; Higano, CS; Hussain, M; Petrylak, DP; Shore, ND | 1 |
| Siegel, JA; Stabin, MG | 1 |
| Cassano, B; De Vincentis, G; Di Castro, E; Follacchio, GA; Frantellizzi, V; Garkavaya, T; Ialongo, P; Lorenzon, L; Mango, L; Pacilio, M; Pani, R; Pellegrini, R; Ventroni, G | 1 |
| Fujimoto, N | 1 |
| Dreicer, R | 1 |
| Armstrong, AJ; Li, J | 1 |
| Boccardo, F; Bombardieri, E; Ceresoli, GL; Evangelista, L | 1 |
| Bloemendal, HJ; de Klerk, JM; Hoekstra, OS; Hooft, L; Jong, JM; Oprea-Lager, DE; van den Eertwegh, AJ; Verheul, HM | 1 |
| Araujo, JC; Etchebehere, EC; Macapinlac, HA; Milton, DR; Rohren, EM; Swanston, NM | 1 |
| Chowdhury, S; Gilson, C; Kirby, R; Manickavasagar, T | 1 |
| Nieder, C; Norum, J; Olsen, JA; Totth, A; Traasdahl, ER | 1 |
| Cassano, B; Di Castro, E; Ialongo, P; Lorenzon, L; Mango, L; Pacilio, M; Recine, F; Sternberg, CN; Ventroni, G | 1 |
| Abou, DS; Doucet, M; Hobbs, RF; Riddle, RC; Thorek, DL; Ulmert, D | 1 |
| Kirchner, V; Papazyan, JP | 1 |
| Knight, H; McVeigh, G; Umeweni, N | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Ahmadzadehfar, H; Essler, M; Gaertner, F; Schlenkhoff, CD; Schmidt, M | 1 |
| Coel, MN; Kwee, SA; Lee, J; Lee, KH; Sato, MM | 1 |
| Cislo, P; Coleman, RE; Nilsson, S; O'Sullivan, JM; Parker, C; Reuning-Scherer, J; Sartor, O; Shan, M; Vogelzang, NJ; Zhan, L | 1 |
| Barkin, J; Mak, V | 1 |
| Coleman, RE; Hoskin, P; Nilsson, S; Parker, C; Petrenciuc, O; Sartor, O; Staudacher, K; Thuresson, M; Vogelzang, NJ | 1 |
| Balk, M; Bui, CN; Flanders, S; Francis, P; O'Day, K; Oestreicher, N; Popelar, B; Posta, L; Tang, H | 1 |
| Ackermann, CJ; Gillessen, S; Hager, S; Joerger, M; Omlin, A | 1 |
| Gayar, H; Heath, EI; Hwang, C; Joyrich, R; Kim, S; Mamdani, H; Modi, D; Vaishampayan, U | 1 |
| Parker, C | 1 |
| Leeman, J; Morris, MJ; Osborne, JR; Rebeiz, K; Rivera, A; Spratt, DE; Zelefsky, MJ; Zumsteg, ZS | 1 |
| Dellavedova, L; Florimonte, L; Maffioli, LS | 1 |
| Cortesi, E; De Vincentis, G; Follacchio, GA; Frantellizzi, V; Liberatore, M; Monteleone, F | 1 |
| Hino, A; Inoue, T; Kaneko, M; Kaneta, T; Kawano, T; Shizukuishi, K; Sugiura, M; Takano, S; Yamamoto, T; Yoshida, K; Zurth, C | 1 |
| Imamura, Y; Sadar, MD | 1 |
| Bottomley, D; Bruland, Ø; Coleman, RE; Finkelstein, SE; Li, R; Michalski, JM; Nilsson, S; O'Sullivan, JM; Parker, C; Sartor, O; Seger, MA; Vogelzang, NJ | 1 |
| Nishiyama, T | 1 |
| Dan, TD; Den, RB; Doyle, L; Gomella, LG; Pridjian, A; Raval, AJ | 1 |
| Barkin, J | 1 |
| Carles, J; Federhofer, J; Gillessen, S; Gratt, J; Heidenreich, A; Heinrich, D; Lévy, J; Miller, K; Nilsson, S; O'Sullivan, JM; Petrenciuc, O; Saad, F; Tucci, M; Wirth, M | 1 |
| Parker, C; Wilson, JM | 1 |
| Thoma, C | 1 |
| Aarts, MJ; Badrising, SK; Bergman, AM; Coenen, JL; de Jong, IJ; Gelderblom, H; Haanen, JB; Hamberg, P; Kerver, ED; Los, M; van den Berg, HP; van den Eertwegh, AJ; van der Noort, V; van Oort, IM; van Voorthuizen, T; Vrijaldenhoven, S | 1 |
| Coleman, RE; Germino, J; Michalski, JM; Nilsson, S; O'Sullivan, JM; Parker, C; Sartor, O; Thuresson, M; Vogelzang, NJ; Widmark, A; Xu, L | 1 |
| Cotogna, PM; Fiorillo, M; Jacene, HA; Jacobus, S; Ledet, EM; McKay, RR; Sartor, O; Steinberger, AE; Taplin, ME | 1 |
| Bolton, D; Corfield, J; Crozier, J; Joshua, AM; Lawrentschuk, N | 1 |
| Barsegian, V; Bockisch, A; Horn, PA; Lindemann, M; Möckel, D; Müller, SP | 1 |
| Bode, A; Bögemann, M; Konnert, J; Rahbar, K; Stegger, L | 1 |
| Aprile, C; Buroni, FE; Lodola, L; Nano, R; Pasi, F; Persico, MG | 1 |
| Aitoku, Y; Basurto, E; Concialdi, K; DiBonaventura, M; Kimura, G; Ledesma, DA; Matsubara, N; McKinnon, I; Mohamed, AF; Narimatsu, A; Uemura, H; Wang, E; Yamaguchi, A | 1 |
| Baiocco, C; Genovese, S; Poti, C; Scalzi, P; Sirotova, Z; Trevisan, A | 1 |
| Cislo, P; Coleman, RE; Nilsson, S; O'Sullivan, JM; Parker, C; Reuning-Scherer, J; Sartor, O; Vogelzang, NJ; Zhan, L | 1 |
| Albany, C; Alva, A; Anand, A; Campbell, G; Daignault, S; Danchaivijitr, P; George, S; Isharwal, S; McDonald, M; Nordquist, L; Ramos, J; Yentz, S; Yu, EY | 1 |
| Gunturu, K; Kewalramani, T; Tretter, C; Varkaris, A | 1 |
| Eiber, M; Gschwend, J; Krönke, M; Scheidhauer, K; Tauber, R | 1 |
| Ágoston, P; Bíró, K; Böde, I; Bodrogi, I; Dank, M; Géczi, L; Gyergyay, F; Kolonics, Z; Küronya, Z; Nagyiványi, K; Rúzsa, Á; Sinkovics, I; Vajdics, T | 1 |
| Odo, U; Sartor, O; Vasudevamurthy, AK | 1 |
| Alibhai, SMH; Emmenegger, U; Finelli, A; Hotte, SJ; Morgan, SC; Walker-Dilks, C; Winquist, E; Zukotynski, K | 1 |
| Cathomas, R; Daugaard, G; Desax, MC; Dresler, H; Fosboel, MO; Gillessen, S; Gottfried, M; Keizman, D; Mermershtain, W; Mortensen, J; Mueller, J; Neiman, V; Omlin, A; Peer, A; Petersen, PM; Reichegger, H; Rosenbaum, E; Rouvinov, K; Sarid, D | 1 |
| Concepcion, RS; Crawford, ED; Finkelstein, SE; Gomella, LG; Keane, TE; Koo, PJ; O'Sullivan, JM; Petrylak, DP; Saad, F; Shore, N; Sieber, P; Slovin, SF; Stone, NN; Tombal, B; Vogelzang, NJ; Yu, EY | 1 |
87 review(s) available for radium and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Density; Denosumab; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Zoledronic Acid | 2022 |
RADIONUCLIDE THERAPY FOR BONE LESIONS IN CASTRATION-RESISTANT PROSTATE CANCER (STATE-OF-THE-ART LITERATURE REVIEW).
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium | 2022 |
The safety of radium-223 combined with new-generation hormonal agents in bone metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Fractures, Bone; Humans; Male; Network Meta-Analysis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium | 2023 |
Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan.
Topics: Alkaline Phosphatase; Docetaxel; Humans; Male; Pain; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Taiwan; Treatment Outcome | 2023 |
Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary.
Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2023 |
Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice.
Topics: Actinium; Astatine; Bismuth; Bone Neoplasms; Humans; Lead Radioisotopes; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Thorium | 2020 |
[Radium-223 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) : The androgen receptor-independent active agent in the therapeutic sequence].
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radiopharmaceuticals; Radium; Receptors, Androgen | 2020 |
Radium-223 mechanism of action: implications for use in treatment combinations.
Topics: Animals; Bone Neoplasms; Combined Modality Therapy; Disease Models, Animal; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
Topics: Androstenes; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Treatment Outcome; Tumor Microenvironment | 2020 |
Radium-223 as an Approved Modality for Treatment of Bone Metastases.
Topics: Bone Neoplasms; Drug Approval; Humans; Isotope Labeling; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2020 |
Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone and Bones; Bone Neoplasms; Chemoradiotherapy; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome; Tumor Microenvironment | 2020 |
Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Tissue Extracts | 2020 |
Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer.
Topics: Alpha Particles; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Chemoradiotherapy; Humans; Male; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
The potential of PSMA-targeted alpha therapy in the management of prostate cancer.
Topics: Alpha Particles; Animals; Antigens, Surface; Antineoplastic Agents; Drug Development; Glutamate Carboxypeptidase II; Humans; Male; Molecular Targeted Therapy; Precision Medicine; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium | 2020 |
Molecular and Metabolic Imaging of Castration-Resistant Prostate Cancer: State of Art and Future Prospects.
Topics: Androgen Antagonists; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome | 2022 |
Contemporary management of advanced prostate cancer: an evolving landscape.
Topics: Adenocarcinoma; Androstenes; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Disease Management; Docetaxel; Humans; Male; Multicenter Studies as Topic; Nitriles; Phenylthiohydantoin; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Radium; Taxoids; Therapies, Investigational | 2021 |
Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
Topics: Bone Neoplasms; Disease Management; Docetaxel; Humans; Italy; Male; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Taxoids; Treatment Outcome | 2017 |
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Disease-Free Survival; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic | 2017 |
Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2017 |
[Monitoring of treatment for metastatic castration-resistant prostate cancer].
Topics: Abiraterone Acetate; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Docetaxel; Humans; Male; Neoplastic Cells, Circulating; Nitriles; Outcome and Process Assessment, Health Care; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2017 |
The role of bone-targeted therapies for prostate cancer in 2017.
Topics: Androstenes; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Survival Rate; Treatment Outcome | 2017 |
Radium-223 in the therapeutic sequence of metastatic castration-resistant prostate cancer.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2018 |
Treatment strategies in low-volume metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Survival Rate; Taxoids; Tissue Extracts; Tumor Burden | 2017 |
Radium 223 dichloride for prostate cancer treatment.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; DNA Breaks, Double-Stranded; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Tumor Microenvironment | 2017 |
[Radium-223 dichloride in patients with castration-refractory prostate cancer].
Topics: Androstenes; Benzamides; Bone Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Denosumab; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment | 2017 |
Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
Topics: Bone Neoplasms; Clinical Trials as Topic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Treatment Outcome | 2017 |
Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.
Topics: Bone Neoplasms; Humans; Male; Patient Selection; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium | 2018 |
Current treatment strategies for advanced prostate cancer.
Topics: Algorithms; Antineoplastic Agents; Biomarkers, Tumor; Cancer Vaccines; Humans; Male; Neoplasm Recurrence, Local; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Tissue Extracts | 2018 |
Current approaches to incorporation of radium-223 in clinical practice.
Topics: Androstenes; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Receptors, Androgen; Taxoids; Treatment Outcome | 2018 |
Current perspectives on bone metastases in castrate-resistant prostate cancer.
Topics: Animals; Biomarkers, Tumor; Bone Neoplasms; Disease Models, Animal; Disease Progression; Humans; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Prostate cancer - Therapy with radium-223.
Topics: Antineoplastic Agents; Bone Neoplasms; Brazil; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Humans; Male; Placebos; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiotherapy Dosage; Radium; Randomized Controlled Trials as Topic; Risk Factors; Societies, Scientific; Survival Rate | 2017 |
Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations.
Topics: Bone Neoplasms; Clinical Trials, Phase III as Topic; Hematologic Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Treatment Outcome | 2018 |
The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.
Topics: Abiraterone Acetate; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Taxoids; Zoledronic Acid | 2018 |
Targeted alpha therapy using Radium-223: From physics to biological effects.
Topics: Alpha Particles; Animals; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2018 |
Radium-223 for the treatment of metastatic castration-resistant prostate cancer: A window of opportunity.
Topics: Abdominal Neoplasms; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Time Factors; Viscera | 2018 |
Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
Topics: Bone Neoplasms; Clinical Trials as Topic; Humans; Lutetium; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Radium | 2019 |
Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.
Topics: Alpha Particles; Bone Neoplasms; Humans; Male; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiotherapy; Radium; Therapies, Investigational | 2018 |
Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging.
Topics: Bone Neoplasms; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radium; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone.
Topics: Bone Neoplasms; Cancer Pain; Clinical Trials as Topic; Combined Modality Therapy; Drug Therapy; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Survival Analysis; Treatment Outcome | 2019 |
Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives.
Topics: Bone Neoplasms; Clinical Trials as Topic; Humans; Male; Patient Selection; Practice Guidelines as Topic; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2019 |
Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.
Topics: Abiraterone Acetate; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Tissue Extracts | 2019 |
Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.
Topics: Bone Neoplasms; Disease Management; Humans; Male; Patient Selection; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Radium; Samarium; Strontium Radioisotopes | 2019 |
Radium 223 for the treatment of metastatic castration-resistant prostate cancer.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium | 2019 |
Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radiobiology; Radiopharmaceuticals; Radium | 2019 |
The changing role of radium-223 in metastatic castrate-resistant prostate cancer: has the EMA missed the mark with revising the label?
Topics: Europe; Government Agencies; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Safety | 2019 |
The changing landscape in metastatic castration-resistant prostate cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Quality of Life; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Taxoids | 2013 |
Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
Topics: Alpha Particles; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Cancer Vaccines; Chlorides; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Taxoids; Tissue Extracts | 2013 |
[Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
Topics: Alpha Particles; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Cooperative Behavior; Dose-Response Relationship, Radiation; Humans; Interdisciplinary Communication; Male; Palliative Care; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate | 2014 |
Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Survival Rate | 2014 |
Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Taxoids; Tissue Extracts | 2014 |
Practical guide to the use of radium 223 dichloride.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Treatment Outcome | 2014 |
Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2014 |
Pathologic fracture in patients with metastatic prostate cancer.
Topics: Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Zoledronic Acid | 2014 |
Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
Topics: Alpha Particles; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Fractures, Spontaneous; Humans; Male; Pain Management; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium | 2014 |
Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?
Topics: Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids; Tissue Extracts | 2015 |
[Radium-223 treatment of bone metastases from castration-resistant prostate cancer].
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiometry; Radium | 2014 |
Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents.
Topics: Aged; Androstenes; Benzamides; Health Services for the Aged; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Tissue Extracts | 2014 |
[Targeted radionuclide therapy for castration-resistant prostate cancer].
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Strontium Radioisotopes | 2014 |
Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate | 2015 |
Metastatic castration-resistant prostate cancer: time for innovation.
Topics: Androstenes; Antibodies, Monoclonal, Humanized; Benzamides; Clinical Trials, Phase III as Topic; Denosumab; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Receptors, Androgen; Signal Transduction; Taxoids; Tissue Extracts | 2015 |
Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; United States; United States Food and Drug Administration | 2015 |
[Castration resistant prostate cancer 2015].
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2015 |
Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
Topics: Antineoplastic Agents; Attitude of Health Personnel; Bone Neoplasms; Clinical Trials as Topic; Humans; Male; Patient Education as Topic; Patient Selection; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Urology | 2015 |
Metabolism and pharmacokinetics of radium-223 in prostate cancer.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Precision Medicine; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Survival Rate | 2015 |
Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.
Topics: Alpha Particles; Animals; Beta Particles; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Colon; DNA Breaks, Double-Stranded; Female; Gastrointestinal Tract; Half-Life; Humans; Male; Mice; Multiple Myeloma; Neoplasms, Second Primary; Osteogenesis; Osteosarcoma; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiologic Health; Radionuclide Imaging; Radium; Rats; Relative Biological Effectiveness; Tissue Distribution | 2015 |
Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Australia; Disease Progression; Docetaxel; General Practice; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2015 |
Sequencing of agents in castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids; Tissue Extracts; Treatment Outcome | 2015 |
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Topics: Androgen Receptor Antagonists; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Enzyme Inhibitors; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Pain; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Spinal Cord Compression; Zoledronic Acid | 2015 |
Targeting bone metastases in prostate cancer: improving clinical outcome.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Osteoblasts; Osteolysis; Pain; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Treatment Outcome; Zoledronic Acid | 2015 |
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Tissue Extracts | 2015 |
Novel agents for castration-resistant prostate cancer: Early experience and beyond.
Topics: Antineoplastic Agents; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2016 |
Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.
Topics: Antineoplastic Agents; Bone Neoplasms; Cancer Pain; Etidronic Acid; Humans; Male; Organometallic Compounds; Organophosphorus Compounds; Palliative Care; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic; Strontium; Strontium Radioisotopes | 2016 |
Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature.
Topics: Aged; Cost-Benefit Analysis; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiotherapy; Radium | 2015 |
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid | 2016 |
Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review.
Topics: Androgen Receptor Antagonists; Benzamides; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Platinum Compounds; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Treatment Outcome | 2016 |
Radium-223 dichloride in clinical practice: a review.
Topics: Bone Neoplasms; Comorbidity; Evidence-Based Medicine; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Radium; Survival Rate; Treatment Outcome | 2016 |
Interim Results From ERADICATE: An Open-Label Phase 2 Study of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Castration-Resistant Prostate Cancer Subjects With Symptomatic Bone Metastases.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Humans; Male; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Treatment Outcome | 2016 |
Radium-223 (Ra-223) Re-Treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC).
Topics: Antineoplastic Agents; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Male; Multicenter Studies as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment; Treatment Outcome | 2016 |
Phase II Clinical Study of Radium-223 Chloride (BAY 88-8223) in Japanese Patients With Symptomatic Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases.
Topics: Antineoplastic Agents; Biomarkers; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2016 |
Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
Topics: Androgen Antagonists; Androgens; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Receptors, Androgen | 2016 |
The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Survival Rate; Treatment Outcome | 2016 |
Understanding the role of new systemic agents in the treatment of prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Taxoids; Tissue Extracts | 2016 |
Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer.
Topics: Bone Neoplasms; Economics, Pharmaceutical; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium | 2016 |
Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Topics: Absorptiometry, Photon; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Evidence-Based Medicine; Fractures, Bone; Humans; Imidazoles; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II).
Topics: Androgens; Androstenes; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2017 |
48 trial(s) available for radium and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases.
Topics: Bone Neoplasms; Cancer Pain; Humans; Male; Pentetic Acid; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium | 2022 |
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial.
Topics: Abiraterone Acetate; Androgen Antagonists; Benzamides; Bone Neoplasms; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Receptors, Androgen | 2022 |
Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
Topics: Antineoplastic Agents; Humans; Male; Neutropenia; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms, Castration-Resistant; Radium | 2023 |
Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response.
Topics: Bone Neoplasms; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2023 |
Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Disease Progression; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate | 2019 |
A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bone Neoplasms; Disease-Free Survival; Double-Blind Method; Fractures, Bone; Humans; Male; Middle Aged; Placebos; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome | 2020 |
Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Chemoradiotherapy; Collagen Type I; Humans; Male; Middle Aged; Nitriles; Peptides; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Survival Rate | 2020 |
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2020 |
Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer -5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life.
Topics: Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radium; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome | 2020 |
Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer.
Topics: Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radium | 2020 |
Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: A single-arm phase 3 study.
Topics: Bone Neoplasms; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2021 |
Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Marrow; Humans; L-Lactate Dehydrogenase; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Survival Analysis | 2020 |
Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Chemoradiotherapy; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Survival Rate; Tissue Extracts | 2021 |
A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Tomography, X-Ray Computed | 2021 |
Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223.
Topics: Bone Neoplasms; Fractures, Bone; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Whole Body Imaging | 2021 |
A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer.
Topics: Humans; Male; Pain; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium | 2021 |
A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Combined Modality Therapy; Double-Blind Method; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium | 2021 |
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Chemoradiotherapy; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate | 2021 |
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
Topics: Alkaline Phosphatase; Biomarkers, Tumor; Humans; Kallikreins; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Multivariate Analysis; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Treatment Outcome | 2017 |
Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
Topics: Aged; Alkaline Phosphatase; Anemia; Asian People; Bone Neoplasms; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Thrombocytopenia; Treatment Outcome | 2017 |
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents; Bone Neoplasms; Humans; Lymphocyte Count; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2018 |
Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Neoplasms; Humans; Kallikreins; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Re-Irradiation | 2017 |
eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Treatment Outcome | 2018 |
Radium-223 international early access program: results from the Spanish subset.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Disease Progression; Disease-Free Survival; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Spain | 2018 |
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Topics: Aged; Aged, 80 and over; Androstenes; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2019 |
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Alpha Particles; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium; Safety; Time Factors; Treatment Outcome | 2019 |
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Abiraterone Acetate; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Double-Blind Method; Fractures, Bone; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Topics: Administration, Intravenous; Aged; Anemia; Bone Neoplasms; Follow-Up Studies; Hematologic Diseases; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radiation Injuries; Radioisotopes; Radium | 2019 |
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Female; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
Topics: Aged; Alkaline Phosphatase; Biomarkers, Tumor; Biopsy; Bone and Bones; Bone Neoplasms; Cadherins; Core Binding Factor Alpha 1 Subunit; Disease Progression; Gene Expression; Humans; Male; Molecular Targeted Therapy; Neoplastic Cells, Circulating; Osteonectin; Osteopontin; Prostate; Prostatic Neoplasms, Castration-Resistant; Radium; Survival Analysis; Tumor Microenvironment | 2019 |
Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Survival Rate; Treatment Outcome | 2019 |
Compartmental Model for
Topics: Alpha Particles; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Humans; Intestine, Large; Intestine, Small; Male; Models, Biological; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2019 |
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Dose-Response Relationship, Radiation; Endpoint Determination; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Tissue Distribution | 2013 |
Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.
Topics: Aged; Animals; Bone Neoplasms; Double-Blind Method; Drug Approval; Humans; Kaplan-Meier Estimate; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Treatment Outcome; United States; United States Food and Drug Administration | 2014 |
Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Alpha Particles; Antineoplastic Agents; Body Weight; Bone and Bones; Bone Neoplasms; Chlorides; Dose-Response Relationship, Radiation; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radiation Protection; Radioisotopes; Radiopharmaceuticals; Radium; Time Factors; Treatment Outcome | 2014 |
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium | 2014 |
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPC
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2014 |
Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Blood Cells; Combined Modality Therapy; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2017 |
Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Bone Neoplasms; Bone Remodeling; Collagen Type I; Docetaxel; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Staging; Peptides; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases.
Topics: Aged; Body Burden; Bone Neoplasms; Humans; Male; Metabolic Clearance Rate; Middle Aged; Organ Specificity; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radioisotopes; Radiopharmaceuticals; Radium; Tissue Distribution; Treatment Outcome; Whole-Body Counting | 2015 |
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.
Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Standard of Care; Taxoids; Treatment Outcome | 2016 |
Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Placebos; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Treatment Outcome | 2016 |
Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases.
Topics: Aged; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radioisotopes; Radiometry; Radiotherapy Dosage; Radium; Tissue Distribution | 2016 |
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Double-Blind Method; Drug Monitoring; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Analysis; Symptom Assessment; Treatment Outcome | 2016 |
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoradiotherapy; Follow-Up Studies; Humans; Male; Neoplasm Grading; Neoplasm Staging; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate | 2016 |
Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Double-Blind Method; Humans; Incidence; Male; Middle Aged; Neutropenia; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Risk Factors; Thrombocytopenia | 2017 |
Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Humans; Interferon-gamma; Lymphatic Metastasis; Lymphocyte Activation; Lymphocytes; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radioisotopes; Radiopharmaceuticals; Radium; Sentinel Lymph Node; Treatment Outcome | 2017 |
Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Double-Blind Method; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium | 2017 |
186 other study(ies) available for radium and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
Topics: Humans; Lymphocytes; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2022 |
A VISION of ALSYMPCA.
Topics: Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2022 |
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Benzamides; Bone Neoplasms; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2022 |
[Exploratory Analysis Results from Post-marketing Surveillance Study of Radium-223 in Japanese Patients with Castration-resistant Prostate Cancer and Bone Metastases: Subgroup Analysis by Age].
Topics: Aged; Bone Neoplasms; Humans; Japan; Laboratories, Clinical; Male; Product Surveillance, Postmarketing; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2021 |
A qualitative research study in Japan investigating patients' experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Cost of Illness; Decision Making; Humans; Interviews as Topic; Japan; Male; Middle Aged; Physicians; Prostatic Neoplasms, Castration-Resistant; Qualitative Research; Quality of Life; Radium | 2021 |
mRNA and small RNA gene expression changes in peripheral blood to detect internal Ra-223 exposure.
Topics: Bone Neoplasms; Gene Expression; Humans; Male; MicroRNAs; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; RNA, Messenger | 2022 |
Combination therapy with radium-223 and enzalutamide in castration-resistant prostate cancer.
Topics: Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium | 2021 |
Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study.
Topics: Aged; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2022 |
Radium-223 Dichloride in Peritoneal Dialysate Following Treatment of Metastatic Castration-resistant Prostate Cancer.
Topics: Bone Neoplasms; Dialysis Solutions; Humans; Male; Peritoneal Dialysis; Prostatic Neoplasms, Castration-Resistant; Radium | 2022 |
Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability.
Topics: Androgen Antagonists; Cyclin-Dependent Kinases; DNA; DNA Damage; Humans; Immunotherapy; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2022 |
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223.
Topics: Androgen Antagonists; Benchmarking; Fluorodeoxyglucose F18; Humans; Male; Muscle, Skeletal; Positron Emission Tomography Computed Tomography; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2022 |
Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Case-Control Studies; Chemoradiotherapy; Ethinyl Estradiol; Humans; Japan; Kallikreins; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Analysis; Treatment Outcome | 2022 |
Reply: A VISION of ALSYMPCA.
Topics: Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2022 |
Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan.
Topics: Alkaline Phosphatase; Bone Neoplasms; Humans; Male; Pain; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Retrospective Studies; Taiwan; Tertiary Care Centers; Treatment Outcome | 2022 |
Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study.
Topics: Aged; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2022 |
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).
Topics: Aged; Bone Neoplasms; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retrospective Studies; Treatment Outcome | 2022 |
Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis.
Topics: Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2023 |
Radium-223 in the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Female; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2022 |
Ocular complications with the use of radium-223: a case series.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radium | 2022 |
The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Topics: Bone Neoplasms; Humans; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2022 |
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy.
Topics: Alkaline Phosphatase; Analgesics, Opioid; Bone Neoplasms; Hemoglobins; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Psychological Distress; Quality of Life; Radium | 2023 |
Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study.
Topics: Bone Neoplasms; Clinical Trials as Topic; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2022 |
[Retrospective practice-related care research study on therapy of mCPRC with radium-223 dichloride].
Topics: Bone Neoplasms; Fractures, Bone; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2022 |
Real World Outcomes in Patients With Metastatic, Castration-Resistant Prostate Cancer Treated With Radium-223 in Routine Clinical Practice in Sweden.
Topics: Bone Neoplasms; Fractures, Bone; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Sweden | 2023 |
Efficacy and Safety of Radium-223 for Castration-resistant Prostate Cancer With Bone Metastasis Before and After Docetaxel.
Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2022 |
Safety and Survival Outcomes of
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2023 |
Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study.
Topics: Anemia; Bone Neoplasms; Female; Humans; Male; Pain; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2023 |
Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) T
Topics: Bone Neoplasms; East Asian People; Humans; Male; Nomograms; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2023 |
The current evidence on prognostic factors in metastatic castration-resistant prostate cancer patients treated with Radium-223.
Topics: Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium | 2022 |
Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters.
Topics: Bone and Bones; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2023 |
The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2023 |
Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model.
Topics: Benzamides; Bone Neoplasms; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium | 2023 |
Sarcopenia in Men With Bone-Predominant Metastatic Castration-Resistant Prostate Cancer Undergoing Ra-223 Therapy.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Sarcopenia | 2023 |
Complete Cycles of Radium-223 Improve Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2023 |
Treatment outcomes of radium-223 in patients with metastatic castration-resistant prostate cancer: An experience before National Health Insurance reimbursement in Taiwan.
Topics: Humans; Insurance, Health, Reimbursement; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Taiwan; Treatment Outcome | 2023 |
Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2023 |
Editorial Comment to Bone-modifying agents are protective for symptomatic skeletal events in radium-223 treatment.
Topics: Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2023 |
Radium-223 and bone metastatic disease: still more to learn.
Topics: Bone Neoplasms; Humans; Magnetic Resonance Imaging; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2023 |
Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group.
Topics: Humans; Male; Neoplasm Metastasis; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radium | 2020 |
Considering bone health in the treatment of prostate cancer bone metastasis based on the results of the ERA-223 trial.
Topics: Abiraterone Acetate; Bone Density; Bone Neoplasms; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium | 2020 |
High-Dose Testosterone and Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer.
Topics: Administration, Topical; Drug Administration Schedule; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Testosterone; Treatment Outcome | 2019 |
Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Chemoradiotherapy, Adjuvant; Disease Progression; Follow-Up Studies; Humans; Male; Neoplasm Grading; Prognosis; Prostate; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Survival Analysis; Treatment Outcome | 2019 |
Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Software; Survival Analysis | 2019 |
A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Registries; Taxoids | 2020 |
Radium and targeted alpha therapy in prostate cancer: new data and concepts.
Topics: Bone and Bones; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2020 |
Three years' clinical practice of Radium-223 therapy in patients with symptomatic bone metastases from metastatic castrate-resistant prostate cancer: a single-centre experience.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
The Relationship Between Total Lesion Activity on
Topics: Aged; Aged, 80 and over; Alpha Particles; Bone and Bones; Bone Neoplasms; Choline; Feasibility Studies; Fluorine Radioisotopes; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retrospective Studies; Treatment Outcome | 2020 |
Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori.
Topics: Aged; Aged, 80 and over; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2020 |
Primary Radical Prostatectomy or Ablative Radiotherapy as Protective Factors for Patients With mCRPC Treated With Radium-223 Dichloride: An Italian Multicenter Study.
Topics: Aged; Aged, 80 and over; Brachytherapy; Combined Modality Therapy; Disease Progression; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Prognosis; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Protective Factors; Radioisotopes; Radium; Retrospective Studies; Survival Rate | 2020 |
Preclinical Single Photon Emission Computed Tomography of Alpha Particle-Emitting Radium-223.
Topics: Animals; Autoradiography; Bone and Bones; Bone Neoplasms; Humans; Male; Mice; Models, Animal; Phantoms, Imaging; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Tissue Distribution; Tomography, Emission-Computed, Single-Photon | 2020 |
Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice.
Topics: Androgen Antagonists; Bone Neoplasms; Humans; Longitudinal Studies; Male; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2020 |
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223.
Topics: Abiraterone Acetate; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2020 |
Clinical aspects of mCRPC management in patients treated with radium-223.
Topics: Aged; Alkaline Phosphatase; Anemia; Bone Neoplasms; Cohort Studies; Hemoglobins; Humans; Kaplan-Meier Estimate; Male; Pain; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium | 2020 |
A National Multicenter Study on overall survival in elderly metastatic castrate-resistant prostate cancer patients treated with Radium-223.
Topics: Aged; Bone Neoplasms; Humans; Italy; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2021 |
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [
Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Retrospective Studies; Treatment Outcome | 2021 |
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Denosumab; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Databases, Factual; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retrospective Studies; Survival Rate; Treatment Outcome | 2020 |
Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
Topics: Aged; Biomarkers, Tumor; Cohort Studies; DNA Damage; DNA Mutational Analysis; DNA Repair; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Analysis | 2020 |
Validation of the 3-variable prognostic score (3-PS) in mCRPC patients treated with
Topics: Aged; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retrospective Studies; Treatment Outcome | 2020 |
223Ra-Dichloride Response Evaluation Using 18F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient With Castration-Resistant Metastatic Prostate Cancer.
Topics: Aged; Bone and Bones; Carboxylic Acids; Cyclobutanes; Humans; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2020 |
Bone scan index can be a useful biomarker of survival outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223.
Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Neoplasms; Feasibility Studies; Humans; Image Interpretation, Computer-Assisted; Japan; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Neural Networks, Computer; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radionuclide Imaging; Radium; Retrospective Studies; Risk Assessment; Tomography, X-Ray Computed; Tumor Burden | 2019 |
Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center.
Topics: Aged; Bone Neoplasms; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome; United States | 2021 |
Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.
Topics: Aged; Bone Neoplasms; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2021 |
Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy.
Topics: Aged; Bone Neoplasms; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radium; Retrospective Studies; Surveys and Questionnaires | 2020 |
Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Clinical Decision-Making; Humans; Male; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors | 2020 |
Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC.
Topics: Aged; Bone Neoplasms; Cancer Pain; Humans; Male; Palliative Care; Prostatic Neoplasms, Castration-Resistant; Radium; Retreatment | 2020 |
Radium-223 therapy for metastatic castration-resistant prostate cancer: survival benefit when used earlier in the treatment pathway.
Topics: Aged; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2021 |
Comment on: 'Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer' by De Vincentis et al.
Topics: Bone Neoplasms; DNA Damage; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2021 |
Response to comment on "Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer".
Topics: DNA Damage; DNA Repair; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2021 |
Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Bone Neoplasms; Chemoradiotherapy; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Neoplasm Grading; Patient Selection; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Retrospective Studies; Survival Analysis; Treatment Outcome | 2021 |
Real-world safety and effectiveness of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastasis: exploratory analysis, based on the results of post-marketing surveillance, according to prior chemotherapy status
Topics: Androgens; Bone Neoplasms; Humans; Japan; Male; Product Surveillance, Postmarketing; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2021 |
Radium-223 in the Third-Line Setting in Metastatic Castration-Resistant Prostate Cancer: Impact of Concomitant Use of Enzalutamide on Overall Survival (OS) and Predictors of Improved OS.
Topics: Aged; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2021 |
A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Forecasting; Humans; Male; Middle Aged; Models, Theoretical; Prostatic Neoplasms, Castration-Resistant; Radiotherapy; Radium; Retrospective Studies; Survival Rate | 2021 |
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223.
Topics: Alkaline Phosphatase; Biomarkers; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2021 |
Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
Topics: Aged; Androstenes; Benzamides; Bone Neoplasms; Combined Modality Therapy; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Survival Rate; Veterans | 2021 |
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemoradiotherapy; Docetaxel; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate; Taxoids | 2021 |
Kinetics of radium-223 and its effects on survival, proliferation and DNA damage in lymph-node and bone metastatic prostate cancer cell lines.
Topics: Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Damage; Humans; Kinetics; Lymphatic Metastasis; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2021 |
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Retrospective Studies; Survival Rate; Taxoids | 2021 |
Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
Topics: Academic Medical Centers; Aged; Aged, 80 and over; Bone Neoplasms; Community Health Services; Disease Management; Follow-Up Studies; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate; Treatment Outcome | 2021 |
The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2021 |
Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Cognition; Drug Therapy; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2021 |
Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.
Topics: Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Analysis; Treatment Outcome | 2021 |
Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223.
Topics: Analgesics, Opioid; Humans; Male; Pain; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radium | 2022 |
Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
Topics: Aged; Androstenes; Benzamides; Docetaxel; Drug Costs; Health Care Costs; Humans; Male; Medicare; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; United States | 2017 |
Comparing Clinical Outcomes for Radium-223: Do Older Patients Do Worse?
Topics: Age Factors; Aged; Anemia; Antineoplastic Agents; England; Humans; Male; Neutropenia; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2017 |
Extraction of
Topics: Blood Component Removal; Bone Neoplasms; Dialysis Solutions; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radiation Protection; Radioisotopes; Radiopharmaceuticals; Radium; Renal Dialysis; Treatment Outcome | 2017 |
223Ra-dichloride response in a patient with Paget disease and bone metastases secondary to castration-resistant prostate cancer.
Topics: Aged; Bone Neoplasms; Humans; Male; Osteitis Deformans; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium | 2017 |
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer.
Topics: Expert Testimony; Humans; Male; Neoplasm Metastasis; Patient Satisfaction; Patient Selection; Prostatic Neoplasms, Castration-Resistant; Radium | 2017 |
Response Assessment of 223Ra Treatment: Should a Fluorocholine PET/CT Be Performed?
Topics: Aged; Bone Neoplasms; Choline; Humans; Male; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome | 2017 |
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Hematologic Tests; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Tumor Burden | 2018 |
Soft Tissue Response on 18F-Fluorocholine PET/CT in Metastatic Castrate-Resistant Prostate Cancer Treated With 223Ra-Dichloride: A Possible Abscopal Effect?
Topics: Aged, 80 and over; Choline; Disease Progression; Humans; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2017 |
Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.
Topics: Bone Neoplasms; Clinical Decision-Making; Combined Modality Therapy; Disease Progression; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Prostatic Neoplasms, Castration-Resistant; Radium; Symptom Assessment; Treatment Outcome | 2017 |
Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Time Factors | 2018 |
Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Bone Neoplasms; CD8-Positive T-Lymphocytes; Humans; Interferon-gamma; Interleukin-13; Male; Middle Aged; Prednisone; Programmed Cell Death 1 Receptor; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome; Tumor Necrosis Factor-alpha | 2018 |
223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases: Lessons from Daily Practice.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Male; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies | 2018 |
High-Energy Collimator Is Preferable to Medium-Energy Collimator for Evaluating 223Ra Uptake in Bone Metastasis at 2 Weeks Postinjection.
Topics: Aged, 80 and over; Biological Transport; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radionuclide Imaging; Radium | 2018 |
Lymph Node Response in a Patient With Metastatic Castration-resistant Prostate Cancer Treated With Radium-223.
Topics: Aged; Antigens, Surface; Bone Neoplasms; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Humans; Lymph Nodes; Male; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radium; Survival Analysis; Treatment Outcome | 2018 |
Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Whole-Body Counting | 2018 |
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
Topics: Bone Neoplasms; Europe; Humans; Male; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2018 |
The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Italy; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Retrospective Studies; Taxoids | 2018 |
A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; ROC Curve; Survival Analysis | 2018 |
DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223.
Topics: Aged; Biomarkers, Tumor; Bone Neoplasms; DNA Repair; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Sequence Analysis, DNA; Treatment Outcome | 2018 |
Fatal Intracranial Hemorrhage Due to Thrombocytopenia in a Patient With Castration-Resistant Prostate Cancer Showing Extensive Bone Uptake of Injected 223Ra Dichloride.
Topics: Bone Neoplasms; Humans; Intracranial Hemorrhages; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Thrombocytopenia; Tomography, Emission-Computed, Single-Photon | 2018 |
Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium-223?
Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Neoplasms; Denosumab; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radionuclide Imaging; Radium; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.
Topics: Aged; Aged, 80 and over; Blood; Bone Neoplasms; Choline; Humans; Male; Middle Aged; Pilot Projects; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radium | 2018 |
Narrative medicine in metastatic prostate cancer reveals ways to improve patient awareness & quality of care.
Topics: Adult; Aged; Aged, 80 and over; Caregivers; Critical Pathways; Female; Health Knowledge, Attitudes, Practice; Humans; Italy; Male; Middle Aged; Narrative Medicine; Prostatic Neoplasms, Castration-Resistant; Quality Improvement; Quality of Life; Radiopharmaceuticals; Radium; Surveys and Questionnaires | 2018 |
Comparison of microdosimetry-based absorbed doses to control tumours and clinically obtained tumour absorbed doses in treatments with
Topics: Humans; Male; Monte Carlo Method; Prostatic Neoplasms, Castration-Resistant; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radium | 2018 |
Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Neoplasms; Health Status; Hemoglobins; Humans; Lymphocyte Count; Male; Middle Aged; Neutrophils; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate | 2018 |
Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.
Topics: Bone Neoplasms; Fluorides; Fluorine Radioisotopes; Humans; Male; Positron-Emission Tomography; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium | 2018 |
Radium-223 (Xofigo) with concurrent abiraterone or enzalutamide: predictive biomarkers of improved overall survival in a clinically advanced cohort.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Chemoradiotherapy; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate | 2019 |
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Cell Count; Disease Progression; Follow-Up Studies; Humans; Injections, Intravenous; Male; Neoplastic Cells, Circulating; Prognosis; Progression-Free Survival; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiotherapy Dosage; Radium | 2018 |
Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
Topics: Aged; Alkaline Phosphatase; Biomarkers, Tumor; Bone Neoplasms; Germ-Line Mutation; Humans; Male; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Recombinational DNA Repair; Survival Analysis; Treatment Outcome | 2019 |
[Radium 223 in castration resistant prostate cancer.]
Topics: Antineoplastic Agents; Bone Neoplasms; Forecasting; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2018 |
Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region.
Topics: Adult; Aged; Aged, 80 and over; Follow-Up Studies; Humans; Italy; Lymphocytes; Male; Middle Aged; Neutrophils; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate; Treatment Outcome | 2019 |
Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation.
Topics: Clinical Trials as Topic; Documentation; Humans; Japan; Male; Neoplasm Metastasis; Occupational Exposure; Patient Admission; Patient Care Team; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radiation Exposure; Radioisotopes; Radiologic Health; Radium | 2019 |
Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.
Topics: Androstenes; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Chemoradiotherapy; Follow-Up Studies; Humans; Male; Nitriles; Pain Management; Palliative Care; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Time Factors | 2019 |
Reversibility of castration resistance status after Radium-223 dichloride treatment: clinical evidence and review of the literature.
Topics: Aged; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2019 |
Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al.'s Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Ur
Topics: Abiraterone Acetate; Humans; Male; Neoplasms, Second Primary; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Fractures, Bone; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome | 2019 |
Radionuclide intake risks in the clinical administration of
Topics: Antineoplastic Agents; Humans; Male; Occupational Exposure; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Risk Assessment | 2019 |
Combination therapies in prostate cancer: proceed with caution.
Topics: Abiraterone Acetate; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Updated:
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2019 |
Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Uro
Topics: Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome; Zoledronic Acid | 2019 |
Early use of abiraterone and radium-223 in metastatic prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Early use of abiraterone and radium-223 in metastatic prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Disease Progression; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Soft Tissue Neoplasms; Treatment Outcome | 2019 |
Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome | 2019 |
No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223Radium.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Cancer Pain; Humans; Male; Middle Aged; Pain Measurement; Prostatic Neoplasms, Castration-Resistant; Psychological Distress; Quality of Life; Radium; Retrospective Studies | 2019 |
Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial.
Topics: Abiraterone Acetate; Bone Neoplasms; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments.
Topics: Androstenes; Androstenols; Anilides; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Humans; Imidazoles; Ipilimumab; Male; Naphthalenes; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Quinolines; Quinolones; Radioisotopes; Radium; Taxoids; Thionucleotides; Tissue Extracts | 2013 |
Urological cancer: α-emitting radium-223-additional choices, more unknowns.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Urologic Neoplasms | 2013 |
Prostate cancer bone metastases: not so systemic after all.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2014 |
The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus.
Topics: Algorithms; Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cancer Vaccines; Humans; Immunosuppressive Agents; Ipilimumab; Lupus Erythematosus, Systemic; Male; Melanoma; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Skin Neoplasms; Tissue Extracts | 2014 |
Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Pain Management; Patient Selection; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium | 2015 |
Effect of docetaxel on safety and efficacy of radium-223.
Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2014 |
Targeted radionuclides for prostate cancer bone metastases.
Topics: Bone Neoplasms; Clinical Trials, Phase IV as Topic; Double-Blind Method; Humans; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic | 2015 |
Disparities in castration-resistant prostate cancer trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Black or African American; Clinical Trials, Phase III as Topic; Healthcare Disparities; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; United States; White People | 2015 |
One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Bone Neoplasms; Disease Progression; Humans; Male; Middle Aged; Pain; Pain Measurement; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retrospective Studies; Treatment Outcome | 2015 |
Re: Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Topics: Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2015 |
Real-time scintigraphic assessment of intravenous radium-223 administration for quality control.
Topics: Administration, Intravenous; Alpha Particles; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality Control; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Radium; Retrospective Studies | 2015 |
Determination of photon emission probabilities for the main gamma-rays of ²²³Ra in equilibrium with its progeny.
Topics: Bone Neoplasms; Gamma Rays; Germanium; Half-Life; Humans; Male; Photons; Probability; Prostatic Neoplasms, Castration-Resistant; Radium; Spectrometry, Gamma | 2015 |
Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Humans; Male; Occupational Exposure; Patient Education as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic | 2015 |
Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Humans; Kallikreins; Male; Pain; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Tomography, Emission-Computed; Treatment Outcome | 2015 |
Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2015 |
Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone and Bones; Bone Neoplasms; Disease-Free Survival; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Odds Ratio; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Reproducibility of Results; Research Design; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Radiation Dose and Hazard Assessment of Potential Contamination Events During Use of 223Ra Dichloride in Radionuclide Therapy.
Topics: Air Pollutants, Radioactive; Bone Neoplasms; Humans; Inhalation Exposure; Male; Occupational Exposure; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radiation Injuries; Radioactive Hazard Release; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Radium; Skin | 2015 |
Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.
Topics: Adult; Alpha Particles; Biological Transport; Bone Neoplasms; Humans; Kinetics; Male; Organotechnetium Compounds; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiometry; Radium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2016 |
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Brachytherapy; Clinical Decision-Making; Docetaxel; Humans; Male; Neoplasm Metastasis; Pain; Pain Measurement; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radium; Taxoids | 2015 |
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Brachytherapy; Clinical Decision-Making; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Treatment Outcome | 2015 |
Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from (223)Ra-dichloride to new horizons for therapeutic response assessment.
Topics: Humans; Male; Nuclear Medicine; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome | 2016 |
Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome; Tumor Burden | 2016 |
The timing of radium-223 therapy in castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brachytherapy; Combined Modality Therapy; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment; Time Factors; Treatment Outcome | 2015 |
New developments in metastatic prostate cancer therapy.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Staging; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiotherapy; Radium; Risk Assessment; Taxoids; Therapies, Investigational; United Kingdom | 2015 |
A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up.
Topics: Aged; Bone Neoplasms; Chlorides; Dose Fractionation, Radiation; Follow-Up Studies; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radiometry; Radium | 2016 |
Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis.
Topics: Alpha Particles; Animals; Antineoplastic Agents; Autoradiography; Bone Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Tissue Distribution; Tumor Microenvironment; Whole-Body Irradiation | 2016 |
[Good risk/benefit profile of treatment with confirmed alpha emitter].
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2015 |
[Radium dichloride-223 improves symptoms including in the daily clinic].
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2015 |
Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Cancer Vaccines; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Singapore; Taxoids; Tissue Extracts | 2015 |
NICE guidance on radium-223 dichloride for hormone-relapsed prostate cancer with bone metastases.
Topics: Aged; Bone Neoplasms; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Risk Assessment; Survival Rate; Treatment Outcome; United Kingdom | 2016 |
Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer.
Topics: Aged; Anemia; Antineoplastic Agents; Bone Marrow Diseases; Bone Neoplasms; Compassionate Use Trials; Dipeptides; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Oligopeptides; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Radium; Technetium Tc 99m Medronate | 2016 |
Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Cancer Vaccines; Choline; Combined Modality Therapy; Disease Progression; Humans; Kaplan-Meier Estimate; Male; Positron Emission Tomography Computed Tomography; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Tissue Extracts; Tumor Burden; Whole Body Imaging | 2016 |
The primary care physician's role in the monitoring and management of the potential sequelae of the medical treatment of prostate cancer: early and late.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents; Benzamides; Denosumab; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Nitriles; Phenylthiohydantoin; Physicians, Primary Care; Professional Role; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Time Factors | 2016 |
Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Budgets; Docetaxel; Drug Costs; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids; Tissue Extracts; United States | 2016 |
Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer.
Topics: Aged; Antineoplastic Agents; Black or African American; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retrospective Studies; Treatment Outcome; United States; White People | 2016 |
When to initiate treatment with radium-223 in patients with metastatic castration-resistant prostate cancer.
Topics: Biomarkers, Tumor; Bone Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Humans; Male; Neoplasm Metastasis; Patient Selection; Practice Guidelines as Topic; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Time-to-Treatment; Treatment Outcome | 2016 |
Use of radium-223 in men with metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate | 2015 |
Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease.
Topics: Aged; Aged, 80 and over; Brachytherapy; Combined Modality Therapy; Disease Progression; Epidural Neoplasms; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2016 |
Prostate-Specific Antigen Flare Phenomenon During
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium | 2016 |
[Unapproved drugs--radium-223, Sipuleucel-T, ketoconazole].
Topics: Drug Approval; Humans; Ketoconazole; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Tissue Extracts | 2016 |
Dosing, administration, and safety of radium-223: How I do it.
Topics: Antineoplastic Agents; Bone Neoplasms; Canada; Humans; Legislation, Drug; Male; Patient Education as Topic; Patient Selection; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Safety; United States | 2016 |
Updates on radium-223 for castration-resistant prostate cancer presented at the Genitourinary Cancers Symposium, January 7-9, 2016, San Francisco, California.
Topics: Antineoplastic Agents; Bone Neoplasms; Clinical Trials, Phase II as Topic; Congresses as Topic; Health Services; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium | 2016 |
Prostate cancer: Radium-223 safe in combination.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | 2016 |
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Topics: Abdominal Neoplasms; Abiraterone Acetate; Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Retrospective Studies; Survival Analysis; Tissue Extracts; Treatment Outcome | 2017 |
Benefit of 68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride Therapy.
Topics: Aged; Carcinoma; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Oligopeptides; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium | 2016 |
Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment.
Topics: Aged; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Japan; Male; Patient Preference; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2016 |
Evaluation of bone metastases by 18F-choline PET/CT in a patient with castration-resistant prostate cancer treated with radium-223.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Choline; Fluorine Radioisotopes; Humans; Male; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radium | 2017 |
Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retrospective Studies; Survival Rate | 2017 |
Acute Myeloid Leukemia After Radium-223 Therapy: Case Report.
Topics: Aged; Bone Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Prostatic Neoplasms, Castration-Resistant; Radium | 2017 |
[Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Topics: Bone Neoplasms; Dose-Response Relationship, Radiation; Evidence-Based Medicine; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Radium; Symptom Assessment; Treatment Outcome | 2017 |
A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cancer Pain; Humans; Hungary; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Retrospective Studies | 2017 |
Acute Promyelocytic Leukemia After Treatment of Metastatic Castration-Resistant Prostate Cancer With Radium-223.
Topics: Aged; Bone Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Leukemia, Radiation-Induced; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2017 |
Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Kallikreins; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Retrospective Studies; Treatment Outcome | 2017 |